NASH market to expand at a an astonishing CAGR of 45%

The non-alcoholic steatohepatitis (NASH) space across the seven major markets of the USA, France, Germany, Italy, Spain, the UK and Japan, is set to rise from $618 million in 2016 to around $25.3 billion by 2026, representing a very rapid compound annual growth rate of 45%, a new study indicates.

According to research and consulting firm GlobalData’s latest report, major drivers of this impressive growth include the rising rate of obesity and diabetes globally and the launches of multiple late-stage pipeline products, which will transform the market from one dominated by the use of off-label generics to a burgeoning competitive space.

Lakshmi Dharmarajan, managing healthcare analyst for GlobalData, explains: “Currently, the NASH market has no approved therapies and is dependent on off-label agents that only offer sub-optimal safety and efficacy outcomes to patients. However, despite NASH drug developments being historically slow, several companies developing late-stage pipeline drugs for the disease have been actively employing strategies to identify biomarkers in recent years.”